Clinical trials: Systemic Lupus
Lupus Nephritis
Rituximab and Belimumab for Lupus Nephritis
In this experimental study, researchers will try to find out if treatment of lupus nephritis with a combination of rituximab and cyclophosphamide (CTX), or a combination of rituximab and CTX followed by treatment with belimumab…
- Trial name
- CALIBRATE (NCT02260934)
- Testing
- Rituximab, Cyclophosphamide, Prednisone
- Where
- 15 sites in United States
- Volunteers
- 43 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SLE (Systemic Lupus), Chronic Pain
A Multi-component, Person-centered, and Yoga-based Coaching Program for Lupus Chronic Pain
This research will assess the feasibility of a tailored yoga coaching program for reducing pain-related symptoms among people with systemic lupus erythematosus.
- Trial name
- MiPAL (NCT07196072)
- Testing
- MiPAL
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Michigan
Systemic Lupus Erythematosus
A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)
The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of moderately to severely active SLE.
- Trial name
- NCT06456567
- Testing
- Telitacicept
- Where
- 4 sites in United States
- Sponsor
- Vor Biopharma
Lupus Nephritis, Systemic Lupus Erythematosus
Predictors of Remission and Renal Outcomes in Lupus Nephritis in Assuit University Hospitals.
the goal of this opservetional study is to identify predictors of remission and renal outcomes in SLE patients affected with Lupus nephritis.
- Trial name
- NCT06228222
- Testing
- renal biopsy
- Volunteers
- 50 people
- Sponsor
- Assiut University
Autoimmune Pancytopenia, Autoimmune Lymphoproliferative Syndrome (ALPS)
Sirolimus for Autoimmune Disease of Blood Cells
Treatment for patients with autoimmune destruction of blood cells is poor. The part of the body that fights infections is called the immune system and white blood cells (WBCs) are part of the immune system.
- Conditions
- Autoimmune Pancytopenia, Autoimmune Lymphoproliferative Syndrome (ALPS), Evans Syndrome, Idiopathic Thrombocytopenic Purpura
- Trial name
- NCT00392951
- Testing
- sirolimus
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Children's Hospital of Philadelphia
Lupus, Fibromyalgia (FM)
Helping Lupus Patients Manage Fibromyalgia Symptoms Through Emotional Awareness and Expression Therapy (EAET)
The goal of this clinical trial is to learn if a psychotherapy intervention works to relieve widespread pain in patients with lupus.
- Conditions
- Lupus, Fibromyalgia (FM), Chronic Widespread Pain
- Trial name
- EAET (NCT07282392)
- Testing
- Emotional Awareness and Expression Therapy (EAET)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Utah
Systemic Lupus Erythematosus
Healthy Lifestyle Intervention in Patients with Systemic Lupus Erythematosus: the Living Well with Lupus Study
This research program aims to investigate the clinical, physiological, metabolic and molecular effects of lifestyle change in patients with systemic lupus erythematosus with high cardiovascular risk.
- Trial name
- NCT04431167
- Testing
- Living well with Lupus
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- University of Sao Paulo
Systemic Lupus Erythematosus
Study to Determine if Gardasil Vaccine is Safe and Effective in Lupus Patients
Cervical neoplasia is increased in women with SLE most likely due to cervical infection with human papilloma virus (HPV). 70% of cervical cancer is caused by HPV types 16 and 18.
- Trial name
- GARDASIL (NCT01741012)
- Testing
- Gardasil
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Wayne State University
Systemic Lupus Erythematosus
A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus
To evaluate the efficacy and safety of sifalimumab compared to placebo in subjects with moderately to severely active Systemic Lupus Erythematosus (SLE).
- Trial name
- NCT01283139
- Testing
- Sifalimumab 200 mg, Sifalimumab 600 mg, Sifalimumab 1,200 mg
- Where
- 107 sites in United States, Argentina and 20 more
- Volunteers
- 834 people
- Sponsor
- MedImmune LLC
Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic
Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions
The purpose of this study is to determine the safety, efficacy and tolerability of topical R333 ointment in Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) patients with active discoid lesions.
- Trial name
- SKINDLE (NCT01597050)
- Testing
- R932333
- Where
- 15 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- Rigel Pharmaceuticals
Systemic Lupus Erythematosus (SLE)
INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use
INTERSTELLAR study will generate critical prospective real-world evidence on the benefits of adding Anifrolumab to standard of care treatment for SLE in routine clinical practice, to inform physicians, payers and patients.
- Trial name
- INTERSTELLAR (NCT06314282)
- Where
- 32 sites in Argentina, China and 10 more
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Lupus Nephritis
Human Umbilical Cord Mesenchymal Stem Cells Treatment for Lupus Nephritis (LN)
Lupus nephritis (LN) is one of the most serious complications and the main cause of death in patients with systemic lupus erythematosus (SLE).The investigators have investigated the usefulness, and confirmed the efficacy and…
- Trial name
- NCT03580291
- Testing
- Mesenchymal stem cells, Mycophenolate Mofetil
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Lingyun Sun
Systemic Lupus Erythematosus
Scrutinizing the Heterogeneity of SLE: Defining Phenotypes
SLE disease course is characterized by unpredictable relapses and remissions in the majority of patients. However, in a small proportion (approximately 5%), SLE presents with a monophasic pattern, meaning that these patients have…
- Trial name
- NCT03348774
- Where
- Canada
- Volunteers
- 950 people
- Sponsor
- University Health Network, Toronto
Lupus Nephritis
Pre-emptive Treatments in Lupus Nephritis Patients With Serological Reactivation
The optimal management of asymptomatic serological reactivation (ASR) in lupus nephritis (LN) patients remained undefined. This project aims to investigate the impact of pre-emptive treatment on disease relapse in LN patients who…
- Trial name
- NCT04870359
- Testing
- Pre-emptive increase of immunosuppressive treatments, Prednisolone and/or AZA/MMF
- Where
- 2 sites in Hong Kong
- Volunteers
- 49 people
- Sponsor
- The University of Hong Kong
Systemic Lupus
Chemokine (CXCL13) as Anew Marker in Diagnosis of SLE
Systemic lupus erythematosus (SLE) is systemic autoimmune disease characterized by various immunological abnormalities, including dysregulated activation of both T and B lymphocytes with overt production of autoreactive…
- Trial name
- NCT03752983
- Testing
- blood samples
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Assiut University
Systemic Lupus Erythematosus
Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus
The primary purpose of this study is to evaluate the potential effectiveness of 24 weeks of MMF within previously discovered immunologically defined subsets of SLE patients.
- Trial name
- DIVERT (NCT05306873)
- Testing
- Mycophenolate Mofetil, Voclosporin
- Where
- 10 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Systemic Lupus Erythematosus (SLE)
A Clinica Study of SCTC21C in Participants With Systemic Lupus Erythematosus
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SCTC21C in participants with systemic lupus erythematosus
- Trial name
- NCT07538154
- Testing
- SCTC21C
- Volunteers
- 159 people
- Sponsor
- Sinocelltech Ltd.
Lupus Nephritis
Chimeric Antigen Receptors T Cells for Refractory/Recurrent Lupus Nephritis in Children
The goal of this prospective, open, single-arm clinical trial was to evaluate the safety and potential efficacy of CAR T cell therapy in children with refractory/recurrent lupus nephritis.
- Trial name
- CAR-T (NCT06904729)
- Testing
- Low-dose CAR-T cells group, High-dose CAR-T cells group
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Guangzhou Women and Children's Medical Center
Lupus Nephritis
High Quality Evidence of Chinese Lupus Nephritis (HELP)
The investigators are registering LN patients at recruited hospitals and developing a LN database in China. Patients will be follow-up every year, and both baseline and follow-up information will be entered into the registration…
- Trial name
- NCT03001973
- Testing
- No Intervention
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Sun Yat-sen University
Membranous Nephropathy, Lupus Nephritis (LN)
A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis
The primary objectives of this clinical trial is to evaluate the safety and tolerability of HLX79 in combination with HLX01 versus placebo in combination with HLX01 in the treatment of glomerulonephritis.
- Trial name
- NCT07038382
- Where
- 17 sites in China
- Volunteers
- 24 people
- Sponsor
- Shanghai Henlius Biotech
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.